🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hoy es el #DiaMundial contra el #CáncerdeVejiga  GO Norte nos recuerdan la importancia de una detección precoz  #MásQueCongresos💙 youtu.be/b4Fpb5ZFewY

Interesante lectura Artículo de Xavier Marcet

Genes that should be included in germline testing panels by tumor type (including prostate cancer): ASCO guideline just published. ascopubs.org/doi/pdf/10.120…

Latest Results for Javelin 100 bladder trial from ASCO #ASCO24 Avelumab maintenance trial data for pts with low tumor burden. For Non Viseral Metastasis- Median OS -31.4 months -HR- 0.60 For LN only Disease- Median OS 31.9 months ❣- HR - 0.86 For Pelvic and

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

📰 Updated IF for Oncology/Hematology journals

Results from the SWOG S1314 trial validate earlier findings in ATM, RB1, ERCC2, or FANCC predict CR to NAC in muscle-invasive bladder cancer.. not perfect but predictive .. with NPV 86% .. better at predicting presence of disease > absence sciencedirect.com/science/articl… European Urology

Propuesta del GECP para incrementar la calidad de la asistencia.

📣William A Hall, MD presents phase II trial of dose escalated RT and elective nodes in VERY high risk #prostatecancer. ➡️10-year med. F/U ➡️>25% risk of clinical nodal involvement. ➡️outstanding 96% 10-year freedom from distant Mets 💥Hallelujah! #pcsm #ASTRO24

Up to 82% of pregnant surgeons experience miscarriage, preterm delivery, and intrauterine growth restriction. Occupational hazards, including prolonged standing, physical exertion, overnight shifts, and teratogenic exposure, contribute to these risks. ja.ma/4eUXVQn

🔬🧬🩺Este años desde GO Norte hemos enviado dos publicaciones en formato póster en #EMUC24 ESMO - Eur. Oncology European Association of Urology (EAU) ➡️ Échales un vistazo!

Have you ever heard about SDHB deficient renal cell carcinoma 🕵️‍♂️? SDHB-deficient kidney cancer is a rare but highly aggressive tumor, often striking patients at a younger age—typically in their 30s and 40s. 🧬 Linked to hereditary mutations in the SDHB gene, it carries a poor

🔊Reunión PostASCO-GU 🔊 🗓️ 20 de febrero 🕒 17h 📍 Online ✍️ events.tacticsmd.net/actualizacione…

Inmensamente feliz de presentar mi primera investigación en ASCO GU, el mayor congreso de oncología genitourinaria Con esfuerzo, constancia y sobre todo muchísima ilusión, a veces los sueños se cumplen! Y hoy se ha cumplido el sueño de mi vida Esto es solo el principio🚀#GU25

Eternamente agradecida a todo el equipo & coautores, no hay mayor suerte que compartir camino con vosotros Eneko Novo, Ricardo Fernandez, Xabier Elcoroaristizabal, Patricia Ruíz, et al UPV/EHU OSI EEC - Hospital Universitario Cruces Plataforma Genética Genómica IIS Biobizkaia GO Norte #ASONMEC ascopubs.org/doi/10.1200/JC…

Entrega de premios de los talleres y broche final a un gran Curso SOGUG de Cáncer Renal y Tumores Germinales. Nos vamos de Gijón con satisfacción por el nivel cientifico y humano del evento. SOGUG #SomosSOGUG

The Uromigos 🏊‍♀️ 🏊‍♀️ 🏊‍♂️ team below - the race Alfonso Gomez 🏆 🥇 and is coming to the annual meeting in Nashville 7th/8th November #GUtrends25

Combination lenvatinib-tislelizumab for fumarate hydratase-deficient #RenalCellCarcinoma. Promising results for FH-deficient #RCC! Dr. Wen Kong shares data on #lenvatinib + #tislelizumab in 1L treatment—90% ORR, 20% CRs, and universal tumor shrinkage. Could TKI-IO combos

Mary-Claire King to receive the Princesa de Asturias award in Spain for her work in genetics. She is known for identifying BRCA1 and BRCA2 and describing the Hereditary Breast and Ovarian Cancer Syndrome. This just one of her multiple contributions to science. ESMO - Eur. Oncology David Gillespie